Blog Posts

Nicholas DeVito: Gli2 promotes tumor immune evasion and immunotherapy resistance through Wnt and Prostaglandin signaling

Nicholas DeVito/scholars.duke.edu

Feb 26, 2025, 10:32

Nicholas DeVito: Gli2 promotes tumor immune evasion and immunotherapy resistance through Wnt and Prostaglandin signaling

Nicholas DeVito, Assistant Professor of Medicine at Duke University, Division of Medical Oncology, shared a paper he and his colleagues authored on LinkedIn:

“After 7 years of work our manuscript is published in Cancer Research

Here we describe how the hedgehog pathway transcription factor Gli2 promotes tumor immune evasion and immunotherapy resistance through Wnt and Prostaglandin signaling, which can be overcome with clinical pharmacologic inhibitors.

See the tutorial on BlueSky here.”

Gli2 Facilitates Tumor Immune Evasion and Immunotherapeutic Resistance by Coordinating Wnt Ligand and Prostaglandin Signaling

Authors: Nicholas C DeVito et al.

Nicholas DeVito

Balamayooran Theivanthiran Brent A. Hanks cancer Georgia M. Beasley Kaylee A. Villarreal Michael Aksu Michael P. Plebanek Michael Sturdivant Nagendra Yarla Nicholas C. DeVito OncoDaily Oncology Vaibhav Jain Y-Van Nguyen

Top 10 Oncogrants of the Week: Advancing Breakthroughs in Cancer Care

Solange Peters Honored with the IASLC Paul A. Bunn, Jr. Scientific Award 2025

World Radiotherapy Awareness Day, September 7: Recognizing the Hidden Hero of Cancer Care

16 Posts Not to Miss From WCLC 2025 Part 1

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham